

C¹ 1. (Amended) An isolated polypeptide useful in a vaccine [comprising] having an amino acid sequence of a N-terminal choline binding protein A truncate, wherein said amino acid sequence is selected from the sequence set forth in SEQ ID NO 1, active fragments thereof, conserved variants thereof, mutants thereof, analogs thereof, and derivatives thereof.

2. (Amended) The isolated polypeptide of Claim 1, wherein said polypeptide is immunogenic against bacterial infection [the amino acid sequence is set forth in SEQ ID NO 1, including fragments, mutants, variants, analogs, or derivatives, thereof].

3. (Amended) The isolated polypeptide of claim 1, wherein the amino acid sequence is selected from the group consisting of the sequence set forth in SEQ ID NO 3, [including] active fragments thereof, mutants thereof, conserved variants thereof, analogs thereof, [or] and derivatives[,] thereof.

C² 5. (Amended) The isolated polypeptide of claim 1, wherein the amino acid sequence is selected from the group consisting of the sequence set forth in SEQ ID NO 7, [including] active fragments thereof, mutants thereof, variants thereof, analogs thereof, [or] and derivatives[,] thereof.

6. (Amended) The isolated polypeptide of claim 1, wherein the amino acid sequence is selected from the group consisting of the sequence set forth in SEQ ID NO 9, [including] active fragments thereof, mutants thereof, conserved variants thereof, analogs thereof, [or] and derivatives[,] thereof.

7. (Amended) An isolated polypeptide [comprising] having an amino acid [sequence] of a N-terminal choline binding protein A truncate having the amino acid sequence as set forth in SEQ ID NO 24, wherein the polypeptide exhibits [its] a tertiary structure.

C³ 9. (Amended) The isolated polypeptide of claim 7, wherein the polypeptide is made by cleaving a full length choline binding protein A with hydroxylamine, wherein the hydroxylamine cleaves the choline binding protein A at a location corresponding to [amino

c3
acid] position 475 in the consensus sequence set forth in Figure 2, thereby creating the N-terminal choline binding protein A truncate.

c4
13. (Amended) An isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the polypeptide has lectin activity and does not bind to choline, and wherein said amino acid sequence is selected from the group consisting of SEQ ID NOS 1, 3-7 and 9-11, active fragments, conserved variants, analogs and derivatives thereof.

14. (Amended) An isolated immunogenic polypeptide [comprising] having an amino acid sequence of a N-terminal choline binding protein A truncate, and wherein said amino acid sequence is selected from the group consisting of SEQ ID NOS 1, 3-7 and 9-11, active fragments, conserved variants, analogs and derivatives thereof.

15. (Amended) The immunogenic polypeptide of claim 14, wherein the amino acid sequence is set forth in SEQ ID NO 1[, including fragments, mutants, variants, analogs, or derivatives, thereof].

16. (Amended) The immunogenic polypeptide of claim 14, wherein the amino acid sequence is set forth in SEQ ID NO 3[, including fragments, mutants, variants, analogs, or derivatives, thereof].

17. (Amended) The immunogenic polypeptide of claim 14, wherein the amino acid sequence is set forth in SEQ ID NO 7[, including fragments, mutants, variants, analogs, or derivatives, thereof].

18. (Amended) The immunogenic polypeptide of claim 14, wherein the amino acid sequence is set forth in SEQ ID NO 9[, including fragments, mutants, variants, analogs, or derivatives, thereof].

c5
39. (Amended) A pharmaceutical composition for use as a vaccine comprising an immunogenic amount of the polypeptide of claim 1 and a pharmaceutically acceptable adjuvant, carrier or diluent.